GlassScriptPhysician profile
Richard D Patten
NPI 1992813042
$45,480.99
in general payments reported to CMS, 2019-2025
11 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,216 · 2020: $11K · 2021: $8,136 · 2022: $16K · 2023: $6,390 · 2024: $255 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,280 · Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,280.00 |
| Food and Beverage | $620.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $43,116.00 | 2019-2023 | Vns - Vitaria |
| Pfizer INC. | $1,669.70 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $173.29 | 2022-2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $124.61 | 2022-2024 | Onpattro |
| Mallinckrodt Hospital Products INC. | $116.23 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $104.65 | 2024 | Lokelma |
| Merck Sharp & Dohme LLC | $88.90 | 2023-2025 | Verquvo, Capvaxive |
| Edwards Lifesciences Corporation | $28.12 | 2025 | |
| Impulse Dynamics (USA) INC. | $21.17 | 2024 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $20.76 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Patten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.